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 David Cameron has committed to a referendum on a British 
exit from the European Union – the so-called Brexit – before 
the end of 2017, irrespective of whether or not the EU is 
prepared to renegotiate aspects of UK membership. Here we 
reflect on what the Brexit would mean for health services. 
 The EU’s contributions to health services, health professionals 
and patients in the UK are wide-ranging. Some are well 
known as a result of media attention; some are more low-key, 
but nonetheless significant. There is barely an area of health-
services provision that is entirely untouched by the EU. In many 
instances, the UK was the driving force behind beneficial EU 
laws and policies. For example, the patients’ rights directive, 
which secures mobility for patients across the EU, was inspired 
by litigation brought by British patients such as Yvonne Watts, 
who had a hip replacement operation in France, paid for by 
the NHS. Using their free European Health Insurance Cards, 
UK citizens can access emergency healthcare across the EU. 
Contrary to some claims, EU law actually  protects the financial 
security of the NHS from unstructured patient movements 
around Europe, by allowing governments to defend NHS 
financial arrangements from unexpected costs of travelling 
patients trying to short-circuit waiting lists or access unproven 
treatments. Nothing in EU law affects the funding or structure 
of the NHS. Neither will EU membership mean that the 
Transatlantic Trade and Investment Partnership (if agreed) 
does so by the back door – as long as the UK government is 
willing to use its veto to defend the NHS. 
 Since the 1970s, the EU has regulated professional standards 
for access to medical professions, setting broad parameters for 
the training of doctors, nurses and midwives, among others. 
These shared and agreed rules on medical education allow 
medical professionals to work across the EU. Our doctors, 
should they wish to, can work in other EU states with minimum 
red tape. The UK has turned to other EU countries (and 
elsewhere in the world) to fill shortages of medical professionals 
and to cover unpopular shifts and places of work. Brexit would 
not mean that this setup would cease, but it would be more 
difficult to ensure equivalence of professional qualifications and 
individually negotiated agreements would be necessary either 
with each country or with the EU as a whole. If the UK is not 
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part of the EU, it will have to accept EU laws and policies as the 
starting point for those negotiations, rather than being present 
as the EU develops its rules on professional standards. 
 EU law protects patients by setting minimum standards for 
working-time rules across the EU. These rules prevent hospitals 
from forcing doctors and other medical professionals to work 
long hours and have informed discussions about on-call work 
and the quality of care that follows if medical professionals have 
to work without proper breaks or rest. Other EU countries train 
their junior doctors without such long hours, and the quality of 
their training is equivalent to ours. Health and safety at work 
rules coming from the EU protect all employees from workplace 
hazards. 
 Since the thalidomide scandal, the EU has regulated the 
safety of all pharmaceutical products marketed in the EU, 
by enforcing stringent pre-market authorisation rules and 
rules for post-market control, such as pharmacovigilance. 
Patients’ rights organisations recognise the significance of 
these rules, which are designed to protect patients from unsafe 
drugs. The EU has been working actively with international 
organisations, particularly the International Medical Products 
Anti-Counterfeiting Taskforce, to secure the supply chain to 
Europe and to prevent falsified medicines reaching patients. For 
this kind of international problem, we have a greater chance of 
success if we negotiate  en bloc , rather than alone. 
 To access the EU market, new health technologies (including 
biotechnology and nanotechnology) have to respect EU clinical 
trials laws. These laws not only protect patient safety through 
enforcing good clinical practice, but also respect European 
ideas of human dignity and human rights, such as the right 
to privacy and data protection. Trial participants, wherever 
they are, enjoy rights to protection under those EU laws. 
Our rules on use of medical data are informed by EU rules 
protecting human rights. Blood safety standards for the whole 
of the EU protect our patients, and we also have access to EU 
networks that help with organ donation. Our clinicians and 
biomedical researchers have access not only to EU data-sets, 
tissue banks, networks of collaborators and the like, but also to 
significant amounts of EU funding to support research. Losing 
this relationship would have highly damaging effects on our 
research hospitals and universities. 
 In the public health domain, EU rules on matters as wide-
ranging as road infrastructure and transport safety, food and 
product safety, air and water quality, workplace health and 
safety and tobacco regulation have had tangible effects on 
population health. The EU's food regulations go beyond food 
safety, to include nutrition labelling and regulation of health 
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claims (such as ‘good for the heart’), which could mislead 
consumers into thinking foods are healthier than they are. 
Being in the EU allows the UK to share resources when scaling 
up brings clear benefits, such as the EU's rare diseases network, 
or when the nature of health problems necessitates a cross-
border response, such as communicable-disease control. 
 Of course, exit from the EU would not preclude the UK 
from negotiating all these things separately with the different 
countries of the EU, or with the EU as a whole. But the 
outcome of those negotiations cannot be guaranteed, and the 
EU will not allow a non-member country to sit at the table 
when it develops standards in future. The UK will no longer be 
a participant in making policy, but will be ‘taking’ it instead. 
The costs of this approach would therefore greatly outweigh 
the benefits, and trying to negotiate from outside the EU would 
consequently leave our health services more vulnerable than 
they need to be. 
 Perhaps most importantly, however, health and the economy 
are intimately related. Economic decisions (such as a decision to 
follow austerity policies) have profound effects on population 
health, and healthcare systems. Resourcing is constrained; the 
gaps between rich and poor, healthy and unhealthy, the young 
and old and adults all increase; and above all the political and 
social debates about health become framed in narrower ways. 
The UK's global economic position, with the EU as its most 
significant trading partner, will remain unchanged whether we 
remain in the EU or not. If we are not around the table, we will 
not be able to influence EU political and economic decisions, 
laws, and policies. ■
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